Hematologic Oncology Update

Latest Episodes:

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress Jul 16, 2026

Show notes

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:

Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting Jul 09, 2026

Show notes

Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:

Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)
Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)
Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)
Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)

CME information and select publications

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit Jun 28, 2026

Show notes

Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:

Introduction (0:00)
Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)
Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)

CME information and select publications

Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit Jun 24, 2026

Show notes

Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:

Introduction (0:00)
Systemic Mastocytosis — Dr Hunter (9:33)
Myelofibrosis — Dr Yacoub (29:40)

CME information and select publications

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit Jun 18, 2026

Show notes

Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:

Introduction (0:00)
Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)
Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)

CME information and select publications

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit Jun 16, 2026

Show notes

Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:

Introduction (0:00)
Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)
Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)

CME information and select publications

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit Jun 15, 2026

Show notes

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:

Introduction (0:00)
Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)
Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12)
CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33)
Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44)
Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34)

CME information and select publications

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances May 23, 2026

Show notes

Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.

CME information and select publications here.

Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances Apr 20, 2026

Show notes

Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.

CME information and select publications here.

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson Apr 10, 2026

Show notes

Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

CME information and select publications here.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Hematologic Oncology Update

Related Podcasts

Links

Stay Connected